JP2015511964A - Ｔｏｒキナーゼ阻害剤を用いた癌の治療 - Google Patents

Ｔｏｒキナーゼ阻害剤を用いた癌の治療 Download PDF

Info

Publication number
JP2015511964A
JP2015511964A JP2015500599A JP2015500599A JP2015511964A JP 2015511964 A JP2015511964 A JP 2015511964A JP 2015500599 A JP2015500599 A JP 2015500599A JP 2015500599 A JP2015500599 A JP 2015500599A JP 2015511964 A JP2015511964 A JP 2015511964A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pyrazin
tor kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511964A5 (https=
Inventor
シュ，スイチャン
ヘゲ，クリステン，マエ
レイモン，ヘザー
ツジ，トシヤ
サピノソ，リサ
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2015511964A publication Critical patent/JP2015511964A/ja
Publication of JP2015511964A5 publication Critical patent/JP2015511964A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015500599A 2012-03-15 2013-03-14 Ｔｏｒキナーゼ阻害剤を用いた癌の治療 Pending JP2015511964A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611428P 2012-03-15 2012-03-15
US61/611,428 2012-03-15
US201261715327P 2012-10-18 2012-10-18
US61/715,327 2012-10-18
PCT/US2013/031217 WO2013138560A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017218388A Division JP6470822B2 (ja) 2012-03-15 2017-11-13 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Publications (2)

Publication Number Publication Date
JP2015511964A true JP2015511964A (ja) 2015-04-23
JP2015511964A5 JP2015511964A5 (https=) 2016-04-21

Family

ID=48045717

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015500599A Pending JP2015511964A (ja) 2012-03-15 2013-03-14 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2017218388A Active JP6470822B2 (ja) 2012-03-15 2017-11-13 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017218388A Active JP6470822B2 (ja) 2012-03-15 2017-11-13 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Country Status (21)

Country Link
US (1) US20130245028A1 (https=)
EP (1) EP2825171B1 (https=)
JP (2) JP2015511964A (https=)
KR (1) KR102057357B1 (https=)
CN (2) CN109846884A (https=)
AU (2) AU2013202992B2 (https=)
BR (1) BR112014022700A2 (https=)
CA (1) CA2867174C (https=)
EA (1) EA028062B1 (https=)
ES (1) ES2668279T3 (https=)
IL (1) IL234639B (https=)
MX (1) MX359227B (https=)
MY (1) MY198666A (https=)
NI (1) NI201400110A (https=)
NZ (1) NZ628420A (https=)
PH (1) PH12014502047B1 (https=)
SG (1) SG11201405686PA (https=)
TW (1) TWI622395B (https=)
UA (1) UA114194C2 (https=)
WO (1) WO2013138560A1 (https=)
ZA (1) ZA201406708B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US20180369241A1 (en) * 2015-06-24 2018-12-27 Celgene Corporation Treatment of cancer with dnapk inhibitors
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EP2299474B1 (en) * 2008-07-10 2013-01-23 JX Nippon Mining & Metals Corporation Hybrid silicon wafer and method for manufacturing same
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
US8420329B2 (en) * 2008-11-20 2013-04-16 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTONARAKIS ES, ET AL.: "Novel targeted therapeutics for metastatic castration-resistant prostate cancer", CANCER LETTERS, vol. 291, no. 1, JPN6016045338, 2010, pages 1 - 13, ISSN: 0003446557 *
BERK L, ET AL.: "Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 69, no. 5, JPN6016045351, 10 January 2012 (2012-01-10), pages 1369 - 1377, ISSN: 0003446562 *
MORGAN TM, ET AL.: "Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway", CURRENT CANCER DRUG TARGETS, vol. 9, no. 2, JPN6016045346, 2009, pages 237 - 249, ISSN: 0003446560 *
SCHAYOWITZ A, ET AL.: "Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR", BRITISH JOURNAL OF CANCER, vol. 103, no. 7, JPN6016045335, 2010, pages 1001 - 1007, ISSN: 0003446556 *
SCHIEWER MJ, ET AL.: "mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostat", ENDOCRINE-RELATED CANCER, vol. 19, no. 1, JPN6016045341, 9 January 2012 (2012-01-09), pages 1 - 12, ISSN: 0003446558 *
SMITH AM, ET AL.: "ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-res", CARCINOGENESIS, vol. 33, no. 3, JPN6016045348, 9 January 2012 (2012-01-09), pages 572 - 580, ISSN: 0003446561 *
WANG H, ET AL.: "CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer vi", CANCER RESEARCH, vol. 71, no. 14, JPN6016045345, 15 July 2011 (2011-07-15), pages 4866 - 4876, ISSN: 0003446559 *

Also Published As

Publication number Publication date
TW201343166A (zh) 2013-11-01
ZA201406708B (en) 2016-05-25
PH12014502047A1 (en) 2014-12-10
AU2013202992B2 (en) 2015-09-03
BR112014022700A2 (pt) 2020-06-30
EP2825171B1 (en) 2018-03-14
MX359227B (es) 2018-09-20
AU2013202992A1 (en) 2013-10-03
CA2867174A1 (en) 2013-09-19
JP2018058861A (ja) 2018-04-12
SG11201405686PA (en) 2014-10-30
MX2014011116A (es) 2015-04-08
EA028062B1 (ru) 2017-10-31
IL234639A0 (en) 2014-11-30
ES2668279T3 (es) 2018-05-17
MY198666A (en) 2023-09-14
NZ628420A (en) 2016-04-29
PH12014502047B1 (en) 2014-12-10
CA2867174C (en) 2020-06-23
WO2013138560A1 (en) 2013-09-19
KR102057357B1 (ko) 2019-12-18
CN104271138A (zh) 2015-01-07
NI201400110A (es) 2015-01-12
JP6470822B2 (ja) 2019-02-13
HK1202247A1 (en) 2015-09-25
TWI622395B (zh) 2018-05-01
CN109846884A (zh) 2019-06-07
UA114194C2 (uk) 2017-05-10
KR20140138928A (ko) 2014-12-04
EA201491701A1 (ru) 2015-01-30
US20130245028A1 (en) 2013-09-19
AU2015213353A1 (en) 2015-09-03
AU2015213353B2 (en) 2017-07-27
IL234639B (en) 2020-05-31
EP2825171A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6470821B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6470820B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
EP2825170B1 (en) Treatment of cancer with tor kinase inhibitors
JP2021107461A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2021050213A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2016516671A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの治療
HK1243919B (zh) 利用tor激酶抑制剂治疗癌症
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170711